Department of Microbiology, General Hospital of Nikaia "Agios Panteleimon", 18454 Piraeus, Greece.
Neonatal Intensive Care Unit, General Hospital of Nikaia "Agios Panteleimon", 18454 Piraeus, Greece.
Medicina (Kaunas). 2024 Sep 5;60(9):1457. doi: 10.3390/medicina60091457.
Feto-maternal microchimerism is the bidirectional transfer of cells through the placenta during pregnancy that can affect the health of both the mother and the offspring, even in childhood or adulthood. However, microchimerism seems to have different consequences in the mother, who already has a developed immune system, than in the fetus, which is vulnerable with immature defense mechanisms. Studies have shown that the presence of fetal microchimeric cells in the mother can be associated with reduced fetal growth, pre-eclampsia, miscarriage, premature birth, and the risk of autoimmune disease development in the future. However, some studies report that they may also play a positive role in the healing of maternal tissue, in cancer and cardiovascular disease. There are few studies in the literature regarding the role of maternal microchimeric cells in fetal autoimmunity. Even fewer have examined their association with the potential triggering of autoimmune diseases later in the offspring's life. The objectives of this review were to elucidate the mechanisms underlying the potential association between maternal cells and autoimmune conditions in offspring. Based on our findings, several hypotheses have been proposed regarding possible mechanisms by which maternal cells may trigger autoimmunity. In Type 1 diabetes, maternal cells have been implicated in either attacking the offspring's pancreatic β-cells, producing insulin, differentiating into endocrine and exocrine cells, or serving as markers of tissue damage. Additionally, several potential mechanisms have been suggested for the onset of neonatal lupus erythematosus. In this context, maternal cells may induce a graft-versus-host or host-versus-graft reaction in the offspring, function as effectors within tissues, or contribute to tissue healing. These cells have also been found to participate in inflammation and fibrosis processes, as well as differentiate into myocardial cells, potentially triggering an immune response. Moreover, the involvement of maternal microchimeric cells has been supported in conditions such as juvenile idiopathic inflammatory myopathies, Sjögren's syndrome, systemic sclerosis, biliary atresia, and rheumatoid arthritis. Conversely, no association has been found between maternal cells and celiac disease in offspring. These findings suggest that the role of maternal cells in autoimmunity remains a controversial topic that warrants further investigation.
胎儿-母体微嵌合体是指妊娠期间细胞通过胎盘的双向转移,这种转移可影响母婴双方的健康,甚至在儿童期或成年期也是如此。然而,微嵌合体在已经发育成熟的免疫系统的母亲和防御机制不成熟的胎儿中似乎有不同的后果。研究表明,母亲体内存在胎儿微嵌合细胞与胎儿生长受限、子痫前期、流产、早产以及未来自身免疫性疾病发展的风险有关。然而,一些研究报告称,它们也可能在母亲组织的愈合、癌症和心血管疾病中发挥积极作用。文献中关于母体微嵌合细胞在胎儿自身免疫中的作用的研究很少。更少的研究检查了它们与后代生命中自身免疫性疾病潜在触发因素的关联。本综述的目的是阐明母体细胞与后代自身免疫性疾病之间潜在关联的潜在机制。根据我们的发现,已经提出了几种假设,涉及母体细胞可能引发自身免疫的可能机制。在 1 型糖尿病中,母体细胞被认为攻击后代的胰岛β细胞,产生胰岛素,分化为内分泌和外分泌细胞,或作为组织损伤的标志物。此外,还提出了几种新生儿红斑狼疮发病的潜在机制。在这种情况下,母体细胞可能在后代中引起移植物抗宿主反应或宿主抗移植物反应,在组织中充当效应物,或有助于组织愈合。这些细胞还被发现参与炎症和纤维化过程,并分化为心肌细胞,可能引发免疫反应。此外,在幼年特发性炎性肌病、干燥综合征、系统性硬化症、胆道闭锁和类风湿关节炎等疾病中也支持母体微嵌合细胞的参与。相反,在后代中没有发现母体细胞与乳糜泻之间的关联。这些发现表明,母体细胞在自身免疫中的作用仍然是一个有争议的话题,需要进一步研究。